降钙素原与危重症患者预后的相关性研究  

Role of procalcitonin in prediction of prognosis of critically ill patients

作　　者：吴健[1] 王玉[2] 陈双叶[3] 

机构地区：[1]中国医科大学附属盛京医院麻醉科,沈阳110004 [2]中国医科大学附属盛京医院妇产科,沈阳110004 [3]中国医科大学,沈阳110001

出　　处：《实用药物与临床》2007年第2期77-78,共2页Practical Pharmacy and Clinical Remedies

摘　　要：目的研究血清降钙素原(PCT)水平与危重症患者预后的相关性。方法采用前瞻性研究,对60例危重症患者在入ICU24h内测定血清PCT水平,并记录其急性生理学与慢性健康状况Ⅱ(APACHEⅡ)评分和序贯器官衰竭估计(SOFA)评分,在出院时对预后进行评定。结果预后不良组(无改善+死亡)PCT值为5.84(1.35,29.69)明显高于预后良好组(明显改善+改善)PCT值0.76(0.23,2.96)(P<0.05)。PCT水平与A-PACHEⅡ评分及SOFA评分明显相关(r=0.628,P<0.05;r=0.745,P<0.01)。结论危重症患者血清PCT水平可作为反映其病情严重程度及预后的一个重要指标。Objective To evaluate the performance of procalcitonin （PCT） as the marker of prediction of prognosis of critically ill patients. Methods A total of 60 critically ill patients in ICU were selected. The level of PCT in serum was measured within 24 hours. All patients were scored by acute physiology and chronic health evaluation Ⅱ （A- PACHE Ⅱ ） and sequential organ failure assessment （SOFA）. Their prognosis were evaluated when they leaved hospital. Results There was an obvious increase of PCT in the patients with bad prognosis[5.84 （1.35, 29.69）] as compared with those with good prognosis[ 0.76 （ 0.23, 2.96）, P 〈 0.05 ]. There was significant correlation between serum PCT and APACHE Ⅱ （r=0.558, P〈0.05） or SOFA （r=0.745, P〈0.01） in all patients. Conclusion Serum level of PCT was an important index for the extent of severity and prognosis in critically ill patients.

关 键 词：降钙素原 危重症 急性生理学 慢性健康状况Ⅱ评分 序贯器官衰竭估计评分 预后 

分 类 号：R459.7[医药卫生—急诊医学]